A new CRISPR-based diagnostic platform simultaneously performs thousands of tests to detect viruses, including SARS-CoV-2. In a study published in Nature, researchers adapted microfluidic technology developed in the Blainey Lab and supported in part by the Bridge Project to create chips that can run thousands of tests flexibly configured across different numbers of samples and viruses.